A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
Status:
Recruiting
Trial end date:
2022-06-27
Target enrollment:
Participant gender:
Summary
Eptinezumab is a preventive treatment for migraine. The drug is made from a process that
currently uses yeast cells for production of the drug. The trial researchers want to test
whether using a new production cell line to make eptinezumab will affect the way the drug
behaves in the body. To do this, the researchers will give a single dose of eptinezumab to
healthy participants. Some of the participants will get eptinezumab that has been made from
yeast cells. Others will get eptinezumab made with the new cell line.